Compare KRRO & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRRO | CPIX |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.6M | 59.5M |
| IPO Year | 2019 | 2009 |
| Metric | KRRO | CPIX |
|---|---|---|
| Price | $9.15 | $4.83 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $74.17 | N/A |
| AVG Volume (30 Days) | 216.8K | ★ 284.3K |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,371,000.00 | ★ $41,278,349.00 |
| Revenue This Year | $144.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.21 |
| 52 Week Low | $5.20 | $1.85 |
| 52 Week High | $55.89 | $7.25 |
| Indicator | KRRO | CPIX |
|---|---|---|
| Relative Strength Index (RSI) | 46.21 | 70.59 |
| Support Level | $7.82 | $3.76 |
| Resistance Level | $8.14 | $5.38 |
| Average True Range (ATR) | 0.48 | 0.45 |
| MACD | 0.67 | 0.07 |
| Stochastic Oscillator | 95.38 | 63.89 |
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.